U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888752) titled 'LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma' on March 17.
Brief Summary: A prospective, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61SQ in patients with relapsed/refractory multiple myeloma.
Study Start Date: March 20
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma
Intervention:
BIOLOGICAL: Cell injection
LCAR-M61SQ cells intravenous infusion; Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamid...